Clinical Trials Logo

Clinical Trial Summary

Can probiotic Vivomixx eradicate Extended Spectrum BetaLactam (ESBL) colonization in adult patients?


Clinical Trial Description

Infections due to extended spectrum cephalosporin-resistant Enterobacteriaceae (ESCRE) are a widely recognized public health threat. The prevalence of ESCRE is comparably low in Sweden but is steadily increasing; approximately 5 % of Swedish inhabitants are carrying ESCRE in the gut. ESCRE can lead to infections mainly from urine, abdomen and blood. These infections can be problematic to treat with current available antibiotics and represent a clinical challenge for clinicians around the world with considerable mortality and morbidity. Risk factors for acquiring an ESCRE is e.g. antibiotic treatment, trips to high prevalence countries, family member with ESCRE etc.

The duration of ESCRE carriage is not known. One Swedish study showed that ESCRE carriage can continue despite antibiotic treatment and that false negative cultures in between positive cultures are common. Since few new groups of antibiotics have been developed in the last decades, infections due to ESCRE may be increasingly difficult to treat. The possibility of ESCRE decolonization is therefore a desirable aim, in particular the more virulent enterobacteriaceae strains leading to recurrent clinical infection episodes.

Probiotics are microorganisms marketed as useful bacteria effective locally in the gut. In recent years many studies have focused on potential health benefits in a range of different gastrointestinal diseases e.g. ulcerous colitis, Crohn's disease, antibiotic associated diarrhoea where probiotics potentially have a therapeutic role4. Smaller studies have shown that probiotics possibly can bind and eliminate enteric pathogenic bacteria5-6. A small in vitro study showed that probiotics can be effective against antibiotic resistant bacteria. Larger clinical treatment studies are needed.

ESCRE constitutes a clinical problem and is largely seen in Escherichia coli and klebsiella spp. The investigator's theory is that the probiotic Vivomixx can reject ESCRE and thus decolonize the gut. Vivomixx contains eight different strains of probiotics; Bifidobacterium breve, B. longum, B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, L. bulgaricus, Streptococcus thermophilus and has the best documentation in clinical studies for enteric diseases of today. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03860415
Study type Interventional
Source Lund University
Contact
Status Completed
Phase N/A
Start date February 1, 2017
Completion date April 30, 2019

See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT05502380 - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery Phase 3
Not yet recruiting NCT04462133 - Optimal Tailored Treatment for H. Pylori Infection N/A
Active, not recruiting NCT03535324 - Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT) N/A
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Withdrawn NCT04230746 - Effect of Antibiotics on Urinary Microbiome Early Phase 1
Active, not recruiting NCT03865706 - Inulin for Infections in the Intensive Care Unit Phase 2
Not yet recruiting NCT06028217 - Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
Recruiting NCT05391035 - The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Recruiting NCT05224401 - Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs Phase 3
Not yet recruiting NCT03855709 - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Recruiting NCT03535272 - Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea Phase 3
Recruiting NCT05902299 - Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
Recruiting NCT05293483 - The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Recruiting NCT05561504 - Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Recruiting NCT03606031 - Digestive Microbiota Transplant
Completed NCT01573195 - Merck IISP Stewardship Grant for Antibiotic Best Practices Phase 4
Not yet recruiting NCT03857295 - Infections Following NeuroSurgery (INS)